SecBot SecBot
8-K ·Filed Feb 25, 2026

RVMD

Revolution Medicines, Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed8mo ago SEC0001193125-26-071517
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

The significant increase in R&D spending and substantial 2026 guidance suggests the company is aggressively advancing its clinical pipeline, particularly with multiple Phase 3 trials. Traders should monitor upcoming clinical readouts, especially the RASolute 302 trial in pancreatic cancer expected in 1H 2026, as key value inflection points.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$102.15
T+0 close · Feb 25, 2026 · via day close
Latest settled
+48.37%
T+60 · $151.56
Vs SPY
+40.20%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 26 $102.15entry
  2. T+1 · 9mo ago −0.13%α +0.35% · $102.02
  3. T+5 · 9mo ago −2.46%α −1.30% · $99.64
  4. T+20 · 8mo ago −8.75%α −2.34% · $93.21
  5. T+60 · 6mo ago +48.37%α +40.20% · $151.56
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Revolution Medicines reported its 2025 financial results, highlighting a $1.1 billion net loss on $987.3 million in R&D expenses as it advances a broad late-stage oncology pipeline. The company maintains a strong $2.0 billion cash position and provided 2026 operating expense guidance of $1.6-$1.7 billion, reflecting continued heavy investment in clinical development.

Key Financial Metrics

EPS
$-5.95

Key Facts

  • Cash, cash equivalents and marketable securities were $2.0 billion as of December 31, 2025
  • R&D expenses were $987.3 million for 2025, up from $595.2 million in 2024
  • Net loss was $1.1 billion for 2025, compared to $600.1 million in 2024
  • 2026 GAAP operating expenses are guided to be between $1.6 and $1.7 billion
  • Company is advancing five ongoing Phase 3 trials with three additional Phase 3 trials planned for 2026

Financial Impact

Increased R&D spend by $395.1 million year-over-year to $987.3 million, with 2026 operating expenses expected to grow to $1.6-$1.7 billion

cashR&D expensesnet lossoperating expenses

Risk Factors

  • High cash burn rate with $1.1 billion net loss in 2025
  • Continued heavy investment with 2026 operating expenses guided at $1.6-$1.7 billion
  • Clinical trial readouts may not meet expectations, particularly the pivotal RASolute 302 trial

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-071517
Document: 0001193125-26-071517-index.html0001193125-26-071517
Document: 0001193125-26-071517.txt0001193125-26-071517

US Market Status

Market Closed · Opens in 7h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 25, 2026